Market Cap 10.69M
Revenue (ttm) 0.00
Net Income (ttm) -8.23M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 280,600
Avg Vol 794,718
Day's Range N/A - N/A
Shares Out 11.38M
Stochastic %K 91%
Beta 0.49
Analysts Sell
Price Target $15.50

Company Profile

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It also provides CardiALLO, an allogeneic mesenchymal stem...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 226 0120
Fax: 650 631 3731
Address:
320 Soquel Way, Sunnyvale, United States
DipBuyInvester
DipBuyInvester Aug. 19 at 3:21 PM
$BCDA Momentum play. She will be 5X plus one day that’s not too far imo. Early bird gats the worm.
0 · Reply
ghondonn
ghondonn Aug. 19 at 3:07 PM
$BCDA Maybe day 1 of the required 7 above a dollar. Maybe nasdaq rescinds the letter. Lets close above a dollar today to give them a chance to do it!
0 · Reply
Raycloser
Raycloser Aug. 18 at 10:38 PM
$BCDA Peter bought again. I keep asking the same question: why would he buy if things are supposedly so dire
1 · Reply
Whateverbro
Whateverbro Aug. 18 at 10:13 PM
$BCDA don't worry I have. show meeeeeeee💰
0 · Reply
DipBuyInvester
DipBuyInvester Aug. 18 at 9:18 PM
$BCDA Lock your position before it takes off.
0 · Reply
Jusme
Jusme Aug. 18 at 7:05 PM
$BCDA It’s making EOD compliance run. Will it make it? My money is on the market maker(s)… there reportedly was 1M shares shorted… All it likely takes is 300K shares to cover and we’re over $1. We’ll see…. pass the popcorn!
0 · Reply
DipBuyInvester
DipBuyInvester Aug. 18 at 6:49 PM
$BCDA Setting up nicely.
0 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Aug. 18 at 6:20 PM
$BCDA CEO purchased 5,400 shares at $0.93 for a total of $5,022. Altman Peter now owns 381,115 shares. https://ceo-buys.com
0 · Reply
Wizee13
Wizee13 Aug. 18 at 10:15 AM
$BCDA Tell me guys, how are they gonna survive with this small amount of cash?
1 · Reply
Jusme
Jusme Aug. 17 at 12:23 PM
$BCDA If the BCDA fails to close at or above $1.00 on August 18, Nasdaq will typically issue a formal Minimum Bid Price Deficiency Notice within a few business days (likely by August 19 or August 20). Once that notice is officially issued, BioCardia will be granted an automatic 180-calendar-day compliance period to rectify the issue. To regain compliance, the stock will need to maintain a closing bid price of at least $1.00 for a minimum of 10 consecutive business days before that 180-day window expires.
0 · Reply
Latest News on BCDA
BioCardia Earnings Call Transcript: Q2 2026

Aug 12, 2026, 4:30 PM EDT - 6 days ago

BioCardia Earnings Call Transcript: Q2 2026


BioCardia Quarterly report: Q2 2026

Aug 12, 2026, 4:30 PM EDT - 6 days ago

BioCardia Quarterly report: Q2 2026


BioCardia Earnings release: Q2 2026

Aug 12, 2026, 4:30 PM EDT - 6 days ago

BioCardia Earnings release: Q2 2026


BioCardia issues letter to shareholders on 2026 priorities

2026-06-18T13:24:57.000Z - 2 months ago

BioCardia issues letter to shareholders on 2026 priorities


BioCardia Announces $4.4 Million Financing

Jun 8, 2026, 8:00 AM EDT - 2 months ago

BioCardia Announces $4.4 Million Financing


BioCardia Earnings Call Transcript: Q1 2026

May 15, 2026, 4:30 PM EDT - 3 months ago

BioCardia Earnings Call Transcript: Q1 2026


BioCardia Earnings release: Q1 2026

May 15, 2026, 4:30 PM EDT - 3 months ago

BioCardia Earnings release: Q1 2026


BioCardia Quarterly report: Q1 2026

May 15, 2026, 4:30 PM EDT - 3 months ago

BioCardia Quarterly report: Q1 2026


BioCardia Slides: Corporate presentation

May 13, 2026, 7:00 AM EDT - 3 months ago

BioCardia Slides: Corporate presentation


BioCardia Slides: Corporate presentation

Apr 28, 2026, 7:00 AM EDT - 4 months ago

BioCardia Slides: Corporate presentation


BioCardia Earnings Call Transcript: Q4 2025

Mar 24, 2026, 4:30 PM EDT - 5 months ago

BioCardia Earnings Call Transcript: Q4 2025


BioCardia Earnings release: Q4 2025

Mar 24, 2026, 4:30 PM EDT - 5 months ago

BioCardia Earnings release: Q4 2025


BioCardia Annual report: Q4 2025

Mar 24, 2026, 4:30 PM EDT - 5 months ago

BioCardia Annual report: Q4 2025


BioCardia Reports 2025 Business Highlights and Financial Results

Mar 24, 2026, 4:05 PM EDT - 5 months ago

BioCardia Reports 2025 Business Highlights and Financial Results


BioCardia appoints Slosman to its Board of Directors

2025-12-03T13:16:10.000Z - 9 months ago

BioCardia appoints Slosman to its Board of Directors

NSPR


BioCardia appoints Farhan Shahab as VP, quality

2025-11-24T13:41:01.000Z - 9 months ago

BioCardia appoints Farhan Shahab as VP, quality


BioCardia Earnings Call Transcript: Q3 2025

Nov 12, 2025, 4:30 PM EST - 9 months ago

BioCardia Earnings Call Transcript: Q3 2025


BioCardia Earnings release: Q3 2025

Nov 12, 2025, 4:30 PM EST - 9 months ago

BioCardia Earnings release: Q3 2025


BioCardia Quarterly report: Q3 2025

Nov 12, 2025, 4:30 PM EST - 9 months ago

BioCardia Quarterly report: Q3 2025


BioCardia Proxy statement: Proxy Filing

Nov 3, 2025, 7:00 AM EST - 10 months ago

BioCardia Proxy statement: Proxy Filing


BioCardia regains compliance with Nasdaq listing requirements

2025-10-02T12:10:31.000Z - 11 months ago

BioCardia regains compliance with Nasdaq listing requirements


BioCardia Regains Compliance with Nasdaq Listing Requirements

Oct 2, 2025, 8:00 AM EDT - 11 months ago

BioCardia Regains Compliance with Nasdaq Listing Requirements


BioCardia prices 4.8M shares at $1.25 in public offering

2025-09-18T13:25:16.000Z - 11 months ago

BioCardia prices 4.8M shares at $1.25 in public offering


BioCardia Announces Pricing of Up To $12 Million Public Offering

Sep 18, 2025, 9:15 AM EDT - 11 months ago

BioCardia Announces Pricing of Up To $12 Million Public Offering


BioCardia announces CardiAMP Cell Therapy results

2025-09-18T11:07:02.000Z - 11 months ago

BioCardia announces CardiAMP Cell Therapy results


BioCardia Registration statement: Registration Filing

Sep 17, 2025, 8:00 AM EDT - 1 year ago

BioCardia Registration statement: Registration Filing


BioCardia Registration statement: Registration Filing

Sep 16, 2025, 8:00 AM EDT - 1 year ago

BioCardia Registration statement: Registration Filing


BioCardia Earnings Call Transcript: Q2 2025

Aug 11, 2025, 4:30 PM EDT - 1 year ago

BioCardia Earnings Call Transcript: Q2 2025


BioCardia Quarterly report: Q2 2025

Aug 11, 2025, 4:30 PM EDT - 1 year ago

BioCardia Quarterly report: Q2 2025


BioCardia Earnings release: Q2 2025

Aug 11, 2025, 4:30 PM EDT - 1 year ago

BioCardia Earnings release: Q2 2025


BioCardia Registration statement: Registration Filing

Jul 9, 2025, 8:00 AM EDT - 1 year ago

BioCardia Registration statement: Registration Filing


BioCardia Earnings Call Transcript: Q1 2025

May 14, 2025, 4:30 PM EDT - 1 year ago

BioCardia Earnings Call Transcript: Q1 2025


BioCardia Earnings release: Q1 2025

May 14, 2025, 4:30 PM EDT - 1 year ago

BioCardia Earnings release: Q1 2025


BioCardia Quarterly report: Q1 2025

May 14, 2025, 4:30 PM EDT - 1 year ago

BioCardia Quarterly report: Q1 2025


BioCardia Registration statement: Registration Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

BioCardia Registration statement: Registration Filing


BioCardia Earnings Call Transcript: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

BioCardia Earnings Call Transcript: Q4 2024


BioCardia Earnings release: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

BioCardia Earnings release: Q4 2024


BioCardia Annual report: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

BioCardia Annual report: Q4 2024


BioCardia Earnings Call Transcript: Q3 2024

Nov 13, 2024, 4:30 PM EST - 1 year ago

BioCardia Earnings Call Transcript: Q3 2024


BioCardia Earnings release: Q3 2024

Nov 13, 2024, 4:30 PM EST - 1 year ago

BioCardia Earnings release: Q3 2024


BioCardia Quarterly report: Q3 2024

Nov 13, 2024, 4:30 PM EST - 1 year ago

BioCardia Quarterly report: Q3 2024


BioCardia Registration statement: Registration Filing

Aug 29, 2024, 8:00 AM EDT - 2 years ago

BioCardia Registration statement: Registration Filing


BioCardia Earnings Call Transcript: Q2 2024

Aug 13, 2024, 4:30 PM EDT - 2 years ago

BioCardia Earnings Call Transcript: Q2 2024


BioCardia Quarterly report: Q2 2024

Aug 13, 2024, 4:30 PM EDT - 2 years ago

BioCardia Quarterly report: Q2 2024


BioCardia Earnings release: Q2 2024

Aug 13, 2024, 4:30 PM EDT - 2 years ago

BioCardia Earnings release: Q2 2024


BioCardia Registration statement: Registration Filing

Aug 9, 2024, 8:00 AM EDT - 2 years ago

BioCardia Registration statement: Registration Filing


BioCardia Announces Reverse Stock Split

May 21, 2024, 5:00 PM EDT - 2 years ago

BioCardia Announces Reverse Stock Split


BioCardia Earnings Call Transcript: Q1 2024

May 14, 2024, 4:30 PM EDT - 2 years ago

BioCardia Earnings Call Transcript: Q1 2024


BioCardia Quarterly report: Q1 2024

May 14, 2024, 4:30 PM EDT - 2 years ago

BioCardia Quarterly report: Q1 2024


BioCardia Earnings release: Q1 2024

May 14, 2024, 4:30 PM EDT - 2 years ago

BioCardia Earnings release: Q1 2024


BioCardia Transcript: Status Update

Apr 30, 2024, 3:00 PM EDT - 2 years ago

BioCardia Transcript: Status Update


BioCardia Proxy statement: Proxy Filing

Apr 15, 2024, 8:00 AM EDT - 2 years ago

BioCardia Proxy statement: Proxy Filing


BioCardia Proxy statement: Proxy Filing

Apr 4, 2024, 8:00 AM EDT - 2 years ago

BioCardia Proxy statement: Proxy Filing


BioCardia Earnings Call Transcript: Q4 2023

Mar 27, 2024, 4:30 PM EDT - 2 years ago

BioCardia Earnings Call Transcript: Q4 2023


BioCardia Earnings release: Q4 2023

Mar 27, 2024, 4:30 PM EDT - 2 years ago

BioCardia Earnings release: Q4 2023


BioCardia Annual report: Q4 2023

Mar 27, 2024, 4:30 PM EDT - 2 years ago

BioCardia Annual report: Q4 2023


DipBuyInvester
DipBuyInvester Aug. 19 at 3:21 PM
$BCDA Momentum play. She will be 5X plus one day that’s not too far imo. Early bird gats the worm.
0 · Reply
ghondonn
ghondonn Aug. 19 at 3:07 PM
$BCDA Maybe day 1 of the required 7 above a dollar. Maybe nasdaq rescinds the letter. Lets close above a dollar today to give them a chance to do it!
0 · Reply
Raycloser
Raycloser Aug. 18 at 10:38 PM
$BCDA Peter bought again. I keep asking the same question: why would he buy if things are supposedly so dire
1 · Reply
Whateverbro
Whateverbro Aug. 18 at 10:13 PM
$BCDA don't worry I have. show meeeeeeee💰
0 · Reply
DipBuyInvester
DipBuyInvester Aug. 18 at 9:18 PM
$BCDA Lock your position before it takes off.
0 · Reply
Jusme
Jusme Aug. 18 at 7:05 PM
$BCDA It’s making EOD compliance run. Will it make it? My money is on the market maker(s)… there reportedly was 1M shares shorted… All it likely takes is 300K shares to cover and we’re over $1. We’ll see…. pass the popcorn!
0 · Reply
DipBuyInvester
DipBuyInvester Aug. 18 at 6:49 PM
$BCDA Setting up nicely.
0 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Aug. 18 at 6:20 PM
$BCDA CEO purchased 5,400 shares at $0.93 for a total of $5,022. Altman Peter now owns 381,115 shares. https://ceo-buys.com
0 · Reply
Wizee13
Wizee13 Aug. 18 at 10:15 AM
$BCDA Tell me guys, how are they gonna survive with this small amount of cash?
1 · Reply
Jusme
Jusme Aug. 17 at 12:23 PM
$BCDA If the BCDA fails to close at or above $1.00 on August 18, Nasdaq will typically issue a formal Minimum Bid Price Deficiency Notice within a few business days (likely by August 19 or August 20). Once that notice is officially issued, BioCardia will be granted an automatic 180-calendar-day compliance period to rectify the issue. To regain compliance, the stock will need to maintain a closing bid price of at least $1.00 for a minimum of 10 consecutive business days before that 180-day window expires.
0 · Reply
DipBuyInvester
DipBuyInvester Aug. 17 at 12:07 AM
0 · Reply
DipBuyInvester
DipBuyInvester Aug. 15 at 9:36 AM
$BCDA This is huge • U.S. CardiAMP HF II confirmatory trial enrollment — Ongoing at four active sites (additional patients in queue/scheduled). FDA Q-Sub meeting minutes confirm this trial may support Premarket Approval (PMA). Continued FDA engagement on the program. • Helix delivery catheter — May 2026 De Novo pre-submission meeting with FDA; agency indicated De Novo approval is possible (preferred path is simultaneous with CardiAMP approval; no major safety/performance concerns raised). Company awaiting/formalizing minutes and planning follow-on submission • Other — Peer-reviewed manuscript(s) for CardiAMP HF data; strategic partnership/licensing progress on Helix/Heart3D (for cell/gene/protein delivery) and the allogeneic MSC platform; potential non-dilutive funding discussions Cash as of June 30, 2026 was ~$4.1 million (after ATM raises totaling several million earlier in 2026), with management citing anticipated runway into 2027 and ability to complete the Japan submission
0 · Reply
DipBuyInvester
DipBuyInvester Aug. 15 at 9:33 AM
$BCDA 👀👀👀🔥🔥🔥🔥💪💪🚀🚀🚀👀 This is huge Japan Shonin (approval) submission for CardiAMP Cell Therapy — Targeted for Q4 2026. Japan’s PMDA Consultation Record of Advice supports submission based on the company’s three completed trials in ischemic HFrEF (patients with elevated NTproBNP on stable guideline-directed medical therapy). PMDA noted the outcomes as credible; the initial addressable group is estimated at ~20,000 patients within a larger ~300,000 patient population in Japan. Approval is typically expected ~12 months after filing and could enable reference-country pathways elsewhere. Work remaining includes electronic trial master file completion, Japanese GCP audits, CDISC data structuring, and engaging a Designated Marketing Authorization Holder.
0 · Reply
DipBuyInvester
DipBuyInvester Aug. 15 at 9:27 AM
$BCDA Analyst Views Key points: • H.C. Wainwright (Joseph Pantginis) maintains a Buy rating with a $25 price target (reiterated as recently as June 2026). • Alliance Global Partners has a Buy with a $6 target (as of May 2026). • Consensus/average targets across sources often land around $15.50 (range roughly $6$25), implying very large upside from current levels if milestones hit. Ratings lean Buy/Strong Buy from the primary covering analysts.
0 · Reply
DipBuyInvester
DipBuyInvester Aug. 14 at 7:40 PM
$BCDA At some point 5X imo !! Early bird gets the worm. MARK and SAVE this post‼️
1 · Reply
DipBuyInvester
DipBuyInvester Aug. 14 at 6:42 PM
$GP $BCDA👀👀👀👀🚀🚀🚀🚀🔥🔥💪💪
0 · Reply
DipBuyInvester
DipBuyInvester Aug. 14 at 4:29 PM
$BCDA Candidate for easy 5X!! Early bird gets the worm.
0 · Reply
DipBuyInvester
DipBuyInvester Aug. 14 at 3:59 PM
$BCDA Nice setup. She can spike at some point. Load the boat. Get on the boat before the crowd. Early bird gets the worm.
0 · Reply
DipBuyInvester
DipBuyInvester Aug. 14 at 11:44 AM
$BCDA 👀👀👀👀🔥🔥🔥🔥🚀🚀🚀💪💪
0 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Aug. 13 at 11:45 PM
$BCDA CEO purchased 1,900 shares at $0.92 for a total of $1,748. Altman Peter now owns 375,785 shares. https://ceo-buys.com
0 · Reply
juninho80
juninho80 Aug. 13 at 9:47 AM
$BCDA what a disaster ....
0 · Reply
Merlintrader
Merlintrader Aug. 13 at 9:32 AM
BioCardia (Nasdaq: $BCDA) Stock Hub // BioCardia reported its second quarter on August 12, 2026, and the release led with regulatory progress on three fronts: Japan’s PMDA supporting a submission for approval, the FDA confirming that the ongoing CardiAMP HF II trial may support a Premarket Approval, and the FDA saying De Novo approval of the Helix catheter is possible. https://www.merlintrader.com/biocardia-bcda-stock-hub/
0 · Reply